MBRX vs. VCNX, RVPH, HCWB, NXTC, ACXP, LPCN, XLO, FBIO, NRXP, and VYNE
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Vaccinex (VCNX), Reviva Pharmaceuticals (RVPH), HCW Biologics (HCWB), NextCure (NXTC), Acurx Pharmaceuticals (ACXP), Lipocine (LPCN), Xilio Therapeutics (XLO), Fortress Biotech (FBIO), NRx Pharmaceuticals (NRXP), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical preparations" industry.
Moleculin Biotech (NASDAQ:MBRX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 6.7% of Moleculin Biotech shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Moleculin Biotech and Moleculin Biotech both had 1 articles in the media. Moleculin Biotech's average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.
Moleculin Biotech's return on equity of -87.19% beat Vaccinex's return on equity.
Vaccinex has higher revenue and earnings than Moleculin Biotech.
Moleculin Biotech received 104 more outperform votes than Vaccinex when rated by MarketBeat users. However, 60.00% of users gave Vaccinex an outperform vote while only 53.16% of users gave Moleculin Biotech an outperform vote.
Moleculin Biotech has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
Moleculin Biotech presently has a consensus price target of $35.00, indicating a potential upside of 712.06%. Given Moleculin Biotech's higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Vaccinex.
Summary
Moleculin Biotech beats Vaccinex on 6 of the 11 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
